Kovács Kitti Bernadett, Bencs Viktor, Hudák Lilla, Oláh László, Csiba László
Department of Neurology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.
Int J Mol Sci. 2023 Sep 14;24(18):14067. doi: 10.3390/ijms241814067.
Ischemic stroke, resulting from insufficient blood supply to the brain, is among the leading causes of death and disability worldwide. A potentially severe complication of the disease itself or its treatment aiming to restore optimal blood flow is hemorrhagic transformation (HT) increasing morbidity and mortality. Detailed summaries can be found in the literature on the pathophysiological background of hemorrhagic transformation, the potential clinical risk factors increasing its chance, and the different biomarkers expected to help in its prediction and clinical outcome. Clinicopathological studies also contribute to the improvement in our knowledge of hemorrhagic transformation. We summarized the clinical risk factors of the hemorrhagic transformation of ischemic strokes in terms of risk reduction and collected the most promising biomarkers in the field. Also, auxiliary treatment options in reperfusion therapies have been reviewed and collected. We highlighted that the optimal timing of revascularization treatment for carefully selected patients and the individualized management of underlying diseases and comorbidities are pivotal. Another important conclusion is that a more intense clinical follow-up including serial cranial CTs for selected patients can be recommended, as clinicopathological investigations have shown HT to be much more common than clinically suspected.
缺血性中风是由于大脑血液供应不足引起的,是全球范围内死亡和残疾的主要原因之一。该疾病本身或旨在恢复最佳血流的治疗方法可能会引发一种严重并发症,即出血性转化(HT),这会增加发病率和死亡率。关于出血性转化的病理生理背景、增加其发生几率的潜在临床风险因素以及有望帮助预测其发生和临床结果的不同生物标志物,在文献中可以找到详细的总结。临床病理研究也有助于增进我们对出血性转化的了解。我们从降低风险的角度总结了缺血性中风出血性转化的临床风险因素,并收集了该领域最有前景的生物标志物。此外,还对再灌注治疗中的辅助治疗方案进行了综述和收集。我们强调,为精心挑选的患者选择最佳的血管再通治疗时机以及对基础疾病和合并症进行个体化管理至关重要。另一个重要结论是,鉴于临床病理研究表明HT的实际发生率远高于临床怀疑的情况,对于选定的患者,可以建议进行更密切的临床随访,包括连续的头颅CT检查。